Application study of tirofiban assisted emergency PCI for acute myocardial infarction
Objective To observe the application effect of tirofiban in emergency percutaneous transluminal coronary intervention(PCI)for acute myocardial infarction(AMI).Methods This study is a prospective study.A total of 112 AMI patients admitted to our hospital from June 2022 to June 2023 will be randomly selected.The enrolled patients will be divided into a conventional group(56 cases)and a tirofiban group(56 cases)using computer randomization.Both groups will receive emergency PCI treatment,while the combined group will receive tirofiban adjuvant treatment.The platelet function,myocardial perfusion,myocardial injury,and prognosis of the two groups of patients will be compared.Results Under different treatment regimens,the platelet aggregation rate(PagT)and platelet adhesion rate(PAdT)in the tirofiban group were(35±5)％and(27±5)％,lower than the conventional group[(38±5)％and(30±5)％].The proportion of thrombolysis in myocardial infarction(TIMI)grade 3 and TIMI myocardial perfusion grade(TMPG)3 grade in the tirofiban group was 89.3％(50/56)and 92.9％(52/56),higher than the conventional group[73.2％(41/56)and 76.79％(43/56)].The eTFC of the tirofiban group(31±5)was lower than the conventional group(34±5),and the PI(55±10)％was higher than the conventional group(50±10)％.The MYO,CK-MB,and LDH of the tirofiban group were(60±10)μg/L,(10±2)U/L,and(40.2±10)U/L,lower than the conventional group[(65±10)pg/L,(12±3)U/L,(45±10)U/L].The incidence of poor prognosis in the tirofiban group was 5.4％(3/56)lower than the conventional group 21.4％(12/56)(P＜0.05).Conclusion Assisting emergency PCI with tirofiban can improve platelet function and myocardial perfusion in AMI patients,and has a positive significance in reducing myocardial injury and the risk of adverse prognosis.
万方数据
维普
